Xyzagen, Inc. Highlights Breakthrough Kv7 Channel Opener Chemistry at AES 2024 Pittsboro, NC, December 15, 2024 – Xyzagen, Inc., a leading pharmacokinetics consultancy and boutique
Novel Prodrug Approaches Show Promise in Neuropathic Pain, Epilepsy Treatment and Functional Neurological Seizures CHICAGO, IL, October 10, 2024 — Xyzagen, Inc., a pharmacokinetics consultancy
Xyzagen to Present New Kv7 Channel Opener Chemistry at American Epilepsy Society 2024 Annual Meeting Pittsboro, NC — November 11, 2024 — Xyzagen’s neurology focused
Xyzagen, Inc., announced two poster presentations highlighting its internal Kv7 research programs at the upcoming Society for Neuroscience (SfN) Annual Meeting, in Chicago, IL, Oct
Powering The Evolving Drug Discovery Landscape The pharmaceutical drug discovery industry is evolving. Innovations in the sector are more and more powered by seed, NIH,
BURNABY, British Columbia, April 26, 2017 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today reported the expansion of its ion channel, neurology-focused
1st Order acquired 1OP2198 from an undisclosed third party, and Xenon will have to honor financial responsibilities under that deal. The firm expects to make
